Prognostic significance of transcription factor E2F-1 in bladder cancer: Genotypic and phenotypic characterization

Journal of the National Cancer Institute

Volumn 91, Issue 10, 1999, Pages 874-881

  Rabbani, Farhang ^a   Richon, Victoria M ^a   Orlow, Irene ^a   Lu, Ming Lan ^a   Drobnjak, Marija ^a   Dudas, Maria ^a   Charytonowicz, Elizabeth ^a   Dalbagni, Guido ^a   Cordon Cardo, Carlos ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ADULT; AGED; ARTICLE; BLADDER CANCER; FEMALE; GENE DELETION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0033583822     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.10.874     Document Type: Article

References (58)

1. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
2. Friend SH, Horowitz JM, Gerber MR, Wang XF, Bogenmann E, Li FP, et al. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein [published erratum appears in Proc Natl Acad Sci U S A 1988;85: 2234]. Proc Natl Acad Sci U S A 1987;84: 9059-63.
3. Ishikawa J, Xu HJ, Hu SX, Yandell DW, Maeda S, Kamidono S, et al. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 1991;51: 5736-43.
4. Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992;84:1256-61.
5. Horowitz JM, Park SH, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A 1990;87: 2775-9.
6. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
7. Whyte P, Williamson NM, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins. Cell 1989;56:67-75.
8. Hansen R, Reddel R, Braithwaite A. The transforming oncoproteins determine the mechanism by which p53 suppresses cell transformation: pRb-mediated growth arrest or apoptosis. Oncogene 1995;11:2535-45.
9. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995;87:1524-9.
10. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992;52:2980-3.
11. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54: 6321-4.
12. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994;54:6353-8.
13. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993;365:349-52.
14. Saito M, Helin K, Valentine MB, Griffith BB, Willman CL, Harlow E, et al. Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics 1995;25: 130-8.
15. Johnson DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci U S A 1994;91:12823-7.
16. Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E, Jacks T. Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-) mice. Nat Genet 1998;18:360-4.
17. Singh P, Wong SH, Hong W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 1994;13: 3329-38.
18. Xu G, Livingston DM, Krek W. Multiple members of the E2F transcription factor family are the products of oncogenes. Proc Natl Acad Sci U S A 1995;92:1357-61.
19. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85:537-48.
20. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG Jr, Livingston DM, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996;85:549-61.
21. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Handbook for staging of cancer. Philadelphia (PA): Lippincott, 1993.
22. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5: 874-9.
23. Helin K, Lees JA, Vidal M, Dyson N, Harlow E, Fattaey A. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 1992;70:337-50.
24. Neuman E, Sellers WR, McNeil JA, Lawrence JB, Kaelin WG Jr. Structure and partial genomic sequence of the human E2F1 gene. Gene 1996;173:163-9.
25. Parker LT, Zakeri H, Deng Q, Spurgeon S, Kwok PY, Nickerson DA. AmpliTaq DNA polymerase, FS dye-terminator sequencing: analysis of peak height patterns. Biotechniques 1996;21:694-9.
26. Richon VM, Russo P, Venta-Perez G, Cordon-Cardo C, Rifkind RA, Marks PA. Two cyto-differentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells. Cancer Res 1997;57:2789-98.
27. Cance WG, Bennan MF, Dudas ME, Huang CM, Cordon-Cardo C. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 1990;323:1457-62.
28. Karpeh MS, Brennan MF, Cance WG, Woodruff JM, Pollack D, Casper ES, et al. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer 1995;72:986-91.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
30. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized trials requiring prolonged observation of each patient: II. analysis and examples. Br J Cancer 1977;35: 1-39.
31. Cox DR. Partial likelihood. Biometrika 1975; 62:269-76.
32. Cox DR. Regression models and life tables (with discussion). J Roy Stat Soc B 1972;34: 187-220.
33. Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84:1251-6.
34. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090-4.
35. Lees JA, Saito M, Vidal M, Valentine M, Look T, Harlow E, et al. The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 1993;13:7813-25.
36. Strom DK, Cleveland JL, Chellappan S, Nip J, Hiebert SW. E2F-1 and E2F-3 are functionally distinct in their ability to promote myeloid cell cycle progression and block granulocyte differentiation. Cell Growth Differ 1998;9: 59-69.
37. Pierce AM, Schneider-Broussard R, Philhower JL, Johnson DG. Differential activities of E2F family members: unique functions in regulating transcription. Mol Carcinog 1998;22: 190-8.
38. Weintraub SJ, Chow KN, Luo RX, Zhang SH, He S, Dean DC. Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 1995;375:812-5.
39. Bremner R, Cohen BL, Sopta M, Hamel PA, Ingles CJ, Gallie BL, et al. Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol Cell Biol 1995;15: 3256-65.
40. Adnane J, Shao Z, Robbins PD. The retinoblastoma susceptibility gene product represses transcription when directly bound to the promoter. J Biol Chem 1995;270:8837-43.
41. Hu QJ, Dyson N, Harlow E. The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. EMBO J 1990;9: 1147-55.
42. Chow KN, Dean DC. Domains A and B in the Rb pocket interact to form a transcriptional repressor motif. Mol Cell Biol 1996;16:4862-8.
43. Qin XQ, Chittenden T, Livingston DM, Kaelin WG Jr. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev 1992;6:953-64.
44. Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev 1992;6:177-85.
45. Qian Y, Luckey C, Horton L, Esser M, Templeton DJ. Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol Cell Biol 1992;12:5363-72.
46. Hiebert SW. Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-mediated growth suppression. Mol Cell Biol 1993;13: 3384-91.
47. Qin XQ, Livingston DM, Kaelin WG Jr, Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci U S A 1994;91:10918-22.
48. Shan B, Lee WH. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol 1994;14:8166-73.
49. Kowalik TF, DeGregori J, Schwarz JK, Nevins JR. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol 1995;69: 2491-500.
50. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 1998;4:685-90.
51. Kitagawa M, Higashi H, Suzuki-Takahashi I, Segawa K, Hanks SK, Taya Y, et al. Phosphorylation of E2F-1 by cyclin A-cdk2. Oncogene 1995;10:229-36.
52. Peeper DS, Keblusek P, Helin K, Toebes M, van der Eb AJ, Zantema A. Phosphorylation of a specific cdk site in E2F-1 affects its electrophoretic mobility and promotes pRB-binding in vitro. Oncogene 1995;10: 39-48.
53. Helin K, Wu CL, Fattaey AR, Lees JA, Dynlacht BD, Ngwu C, et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev 1993;7:1850-61.
54. Nakamura T, Monden Y, Kawashima K, Naruke T, Nishimura S. Failure to detect mutations in the retinoblastoma protein-binding domain of the transcription factor E2F-1 inhuman cancers. Jpn J Cancer Res 1996;87: 1204-9.
55. Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 1997; 158:393-9.
56. Pagano F, Bassi P, Galetti TP, Meneghini A, Milani C, Artibani W, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991;145: 45-50.
57. Frazier HA, Robertson JE, Dodge RK, Paulson DF. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1993;71:3993-4001.
58. Heney NM, Proppe K, Prout GR Jr, Griffin PP, Shipley WU. Invasive bladder cancer: tumor configuration, lymphatic invasion and survival. J Urol 1983;130:895-7.